Phase 4Status unknown
Efficacy of Generic vs. Original Rosuvastatin 20 mg and Ezetimibe 10 mg Free-Combination Therapy on LDL-C Reduction: A Non-inferiority Trial
- Sponsor
- Berlin Pharmaceutical Industry Co.,Ltd (Industry)
- Enrollment
- 108 planned
- Conditions
- Hypercholesterolemia in High or Very High Cardiovascular Risk Patients Rosuvastatin, Ezetimibe, Hypercholesterolemia, Dyslipidemia, Cardiovascular Diseases, LDL Cholesterol; Rosuvastatin, Ezetimibe, Hypercholesterolemia, Dyslipidemia, Cardiovascular Diseases, LDL Cholesterol
- Interventions
- Participants will receive the original formulation of Rosuvastatin (Crestor) 20 mg combined with Ezetimibe (Ezetrol) 10 mg orally once daily after dinner for 12 weeks; Active Comparator Drug,Experimental Drug; Original Combination Group,Generic Combination Group
- Ages
- adults, older adults
- Registry
- TCTR20260920003
Full record on the Thai Clinical Trials RegistrySource: WHO ICTRP, processed November 9, 2026
Primary outcomes
- Change in Low-Density Lipoprotein Cholesterol (LDL-C) level 12 weeks Percentage change in blood LDL-C concentration (mg/dL) from baseline.
History
Study completion expected
Last registry update
Started
Registered
In the news
ConferenceAHA Scientific Sessions 2026 (opens AHA Scientific Sessions 2026 in a new tab)
Pelacarsen lowers Lp(a) 78% but shows no cardiovascular benefit in HORIZON trial
Researchers report the seven-year, randomized phase 3 trial compared monthly injections with placebo in more than 8,300 adults with cardiovascular disease and Lp(a) ≥70 mg/dL.
